We’re one of the first firms to deliver coverage of foreign growth companies tailored specifically to U.S. investors.

Research Reports

Our research reports are available to our clients. If you are an existing client and already have a username and password, please login. If you are an existing client and want to register for access to the site, please use the registration form below.

If you are a potential client and are interested in finding out how Chardan can help you, please contact Shai Gerson at 646-465-9008.

Date Company Title Sector Symbol Rating Analystsort icon Document
Lowering To Neutral; Raising PT To $296 Log In or Register
October 17, 2012 NPSP VVUS Healthcare Andrew Fein Log In or Register
November 19, 2012 Neostem Inc. 3Q Update: Believe Data, Acquisitions Could Drive Investor Interest in 2013 Healthcare NBS Buy Andrew Fein Log In or Register
December 11, 2012 Our Thoughts From ASH Healthcare Andrew Fein Log In or Register
February 13, 2013 CEL-SCI Corporation Initiating Coverage with BUY Rating and $0.90 PT Healthcare CVM Buy Andrew Fein Log In or Register
March 11, 2013 Neostem Inc. DSMB Grants All Clear: PreSERVE Continues as Planned Healthcare NBS Buy Andrew Fein Log In or Register
March 20, 2013 Amarin Corporation Initiating with Neutral Rating and $8.50 PT: Not All Squeaks Have Been Oiled Healthcare AMRN Neutral Andrew Fein Log In or Register
April 10, 2013 Vertex Pharmaceuticals Initiating with BUY and $80 PT: A Paradoxical Arbitrage Healthcare VRTX Buy Andrew Fein Log In or Register
April 19, 2013 Vertex Pharmaceuticals Breathing a Sigh of Relief (or Just as We Had Expected) – Raising PT to $105 Healthcare VRTX Buy Andrew Fein Log In or Register
April 23, 2013 Amarin Corporation sNDA for ANCHOR Accepted: A Big So What Healthcare AMRN Neutral Andrew Fein Log In or Register

Coverage Universe

April 1, 2014

To learn more about our Research Group, please contact Jay Srivatsa at 646-465-9065